Notable Quotes
"With this approval, Dupixent once again demonstrates its value in advancing the treatment landscape for a chronic type 2 inflammatory disease with high unmet need. Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids with fewer patients having bone erosion in the sinuses." — on AFRS approval, February 2026
"We have programs that are first in class, the first drug that can really make a difference. Dupixent is a great example of such a drug that has changed an entire landscape for all these allergic diseases." — to shareholders, 2020